
The Santaris management describes the current year and the future of the biotech company in very hopeful terms. Despite the fact that liquid assets at the close of 2011 had shrunk to a mere DKK 54.9 million compared with 124.5 million in 2010, which dropped the cash pool to its lowest level since 2005.
“We expect that the company can secure the needed capital in 2012 through milestone payments from partnership deals, sales of assets, cost reductions and/or through additional financing from the company share holders,” the recently appointed CEO, Henrik Stage, writes in the yearly financial report.
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app